Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Seamlessly bridge your LNP discovery journey from RUO to bulk GLP-tox and GMP excipient-grade material.
Explore CGMP Lipid ServicesSM-102-d4 is intended for use as an internal standard for the quantification of SM-102 (Item No. 33474) by GC- or LC-MS. SM-102 is an ionizable cationic lipid (pKa = 6.68) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and plasmid DNA in vitro and in vivo.1,2 It inhibits inward-rectifying potassium currents mediated by human-ether-a-go-go (hERG), also known as Kv11.1, in GH3 rat pituitary cells and MA-10 mouse Leydig cells (IC50s = 108 and 98 µM, respectively).3 Administration of luciferase mRNA in SM-102-containing LNPs induces hepatic luciferase expression in mice.1 LNPs containing SM-102 and Q1-SM-102 (Item No. 41239) as a cationic lipid pair (CLP) and encapsulating a luciferase reporter induce luciferase expression in the lungs and spleen in mice.4 Intramuscular immunization of LNPs containing SM-102 and encapsulating mRNA encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein increases serum SARS-CoV-2 spike glycoprotein-specific IgG titers in mice.5 LNPs containing SM-102 and encapsulating mRNA encoding β-catenin increase bone volume in a mouse model of tibia fracture repair when administered via injection to the fracture callus.6 Formulations containing SM-102 have been used in the development of LNPs for delivery of mRNA-based vaccines.
WARNING This product is not for human or veterinary use.
1. A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-
2. The expression kinetics and immunogenicity of lipid nanoparticles delivering plasmid DNA and mRNA in mice. Vaccines (Basel) 11(10), 1580 (2023).
3. Effective perturbations on the amplitude and hysteresis of Erg-
4. Cationic lipid pairs enhance liver-
5. mRNA vaccines against SARS-
6. β-